Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels

Clinical Therapeutics

Volumn 37, Issue 9, 2015, Pages 1945-1954.e6

  Roth, Eli M ^a   Bujas Bobanovic, Maja ^b   Louie, Michael J ^c   Cariou, Bertrand ^d  

^a UNIVERSITY OF CINCINNATI   (United States)

^b SANOFI   (France)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

administration; alirocumab; devices; PCSK9; pen; syringe

Indexed keywords

ALIROCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PLACEBO; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DEVICE COMPARISON; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; MEDICAL SPECIALIST; PATIENT ATTITUDE; PERCEPTION; PRE FILLED PEN; PROSTHETIC PAD; RANDOMIZED CONTROLLED TRIAL; SELF INJECTION; SINGLE BLIND PROCEDURE; SYRINGE; WORK EXPERIENCE; AGED; ATTITUDE TO HEALTH; BLOOD; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG SELF ADMINISTRATION; HEALTH PERSONNEL ATTITUDE; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; INJECTION; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; CHOLESTEROL, LDL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; INJECTIONS; MALE; MIDDLE AGED; SELF ADMINISTRATION; SYRINGES;

EID: 84941188547     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.07.008     Document Type: Article

References (16)

1. C. Baigent, L. Blackwell, J. Emberson, and et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. N.J. Stone, J. Robinson, A.H. Lichtenstein, and et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines J Am Coll Cardiol 63 2014 2889 2934
3. Gitt AK, Ambegaonkar B, Brudi P, et al. Low LDL-cholesterol target achievement in statin-treated patients in clinical practice in China and Europe: results of the Dyslipidemia International Study (DYSIS). J Am Coll Cardiol. 2015;65(10-S):A1482.
4. N.D. Wong, C. Patao, K. Wong, and et al. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status Diab Vasc Dis Res 10 2013 505 513
5. N.D. Wong, J. Chuang, K. Wong, and et al. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009-2010) Am J Cardiol 112 2013 373 379
6. N.G. Seidah, and A. Prat The biology and therapeutic targeting of the proprotein convertases Nat Rev Drug Discov 11 2012 367 383
7. C.P. Cannon, B. Cariou, D. Blom, and et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial Eur Heart J 36 2015 1186 1194
8. D.J. Kereiakes, J.G. Robinson, C.P. Cannon, and et al. Efficacy and safety of the PCSK9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study Am Heart J 169 2015 906-915.e13
9. J.G. Robinson, M. Farnier, M. Krempf, and et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1489 1499
10. E.M. Roth, M.R. Taskinen, H.N. Ginsberg, and et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial Int J Cardiol 176 2014 55 61
11. US Food and Drug Administration. FDA news release. FDA approves new orphan drug Kyanmro to treat inherited cholesterol disorder. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337195.htm.
12. J. Lange, P. Richard, and N. Bradley Usability of a new disposable autoinjector platform device: results of a formative study conducted with a broad user population Med Devices (Auckl) 8 2015 255 264
13. S. Tatlock, L. Grant, R. Arbuckle, and et al. Treatment acceptance measure for use in hypercholesterolemia patients receiving treatment via subcutaneous injection Value in Health 17 2014 A569
14. J.J. Kastelein, J.G. Robinson, M. Farnier, and et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies Cardiovasc Drugs Ther 28 2014 281 289
15. Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015 [in press].
16. P.M. Moriarty, T.A. Jacobson, E. Bruckert, and et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial J Clin Lipidol 8 2014 554 561